With the BIO International Convention only three weeks away, Chicago is gearing up to welcome some of the biggest pharmaceutical companies in the world. Québec will be well represented at this international event, as many medications have been discovered and developed there, including EGRIFTA®, the first FDA-approved medicine shown to reduce HIV-related excess belly fat.
EGRIFTA® (tesamorelin for injection) was developed by Theratechnologies, which is a specialty pharmaceutical company that discovers and develops innovative therapeutic peptide products. Theratechnologies was founded in 1993 and is headquartered in Montréal, Canada.
To learn more about EGRIFTA®, please click here.
To learn more about Theratechnologies, please click here.